What people listen to is my reasoned analysis/opinions. In the case of Veru that was my opinion about the data and how it met/exceeded the ph3 statistical goal for an approval. And the Veru panel agreed that the efficacy did indeed meet the endpoint. They were concerned about adequate size database for safety. Soon we will find out if FDA agrees with the ADCOM panel. Since that meeting one thing has changed, the new variants (BQ1.1) are now resistant to the last still effective monoclonal antibody. As seen here in a recent Lancet publication
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00733-2/fulltext# You know primary references and all